Summary The fluorescent stain Hoechst 33342 (H33342) has been employed extensively as an in vivo marker of functional tumour vasculature. We have found that H33342 causes a transient, dose-dependent decrease in tumour red blood cell (RBC) flow in SCCVII tumours as measured using laser Doppler flowmetry. After intravenous bolus injection of 15 mg kg-' to anaesthetised mice, blood flow in subcutaneous back tumours declined to 19 ± 11 % of pretreatment values, returning to normal in < 7 min. The effect was less pronounced in mice bearing foot tumours in which flow decreased to 52± 14% of pretreatment values in unanaesthetised mice and to 50 ± 15% in anaesthetised animals. RBC flow in foot tumours remained significantly depressed for only 2-3 min. A dose of 5 mg kg-' was not significantly vasoactive in back tumours. H33342 also caused a transient 20±6 mmHg decline in mouse arterial blood pressure. Blood pH and haematocrit, and tumour cell oxygen consumption were unchanged by H33342. H33342-induced flow changes did not affect results obtained using an in vivo double staining protocol provided that the interval between stain injections was >5 min. Due to its transient effects on tumour perfusion, the stain caused radiobiological tumour hypoxia if injected immediately prior to X-irradiation. Injection 20 min before irradiation had no influence on tumour radiation response. We conclude that the transient nature of H33342-induced perturbations in mouse cardiovascular physiology and tumour blood flow must always be considered but do not preclude the use of the stain as a vascular marker to detect spontaneous tumour blood flow fluctuations or acute hypoxia.
The bisbenzamide compound Hoechst 33342 (H33342) is a DNA-binding fluorescent stain used extensively in flow cytometry studies to quantify DNA content in live cells (Arndt-Jovin & Jovin, 1977) and to select cells from different locations within multicell spheroids (Durand, 1982) and experimental solid tumours (Chaplin et al., , 1986 Loeffler et al., 1987; Siemann & Keng, 1988; Young & Hill, 1989; Durand et al., 1990) . Perivascular tumour cells avidly bind intravenously injected H33342 and are therefore more brightly fluorescent than cells distant from the blood supply which are exposed to lower dye concentrations. Thus, H33342 acts as a marker of perfused tumour vasculature (Reinhold & Visser, 1983) and can be used to quantify vascular morphology (Smith et al., 1988; Fallowfield, 1989) . The stain has also been employed in double-labelling techniques to identify tumour vessels subject to transient nonperfusion Jirtle, 1988; Trotter et al., 1989a) and to isolate tumour cells which are made acutely hypoxic by these flow fluctuations (Chaplin et al., 1986 Minchinton et al., 1990) . Hoechst-staining methods have also been used to examine the effects of vasoactive drugs (Trotter et al., 1989c) and chemotherapeutic agents (Murray et al., 1987; Zwi et al., 1989) on functional tumour vasculature.
Ideally, vascular markers for use in vivo should have no significant influence on metabolic or physiologic processes. H33342 has been shown to cause DNA damage, cell cycle perturbations, and radioprotection in vitro (Durand & Olive, 1982; Smith & Anderson, 1984; Young & Hill, 1989 ) but these effects generally occur at concentrations much higher than those achievable in vivo. However, decreased tumour perfusion has been observed in some experimental tumours following H33342 administration (Smith et al., 1988; Zwi et al., 1989) . To date, all direct histological and radiobiological evidence for transient perfusion and acute hypoxia in rodent tumours is based on experiments which utilise H33342 staining of tumour perivascular cells. Thus, any influence of H33342 on tumour physiology must be understood before results of experiments employing the stain can be definitively interpreted.
The purpose of this study was to measure the effect of H33342 on mouse cardiovascular and metabolic parameters and the influence of the stain on blood flow and radiation response of murine SCCVII carcinoma. The time course of vasoactive effects, if they occur, is of critical importance since a short-lived, reversible change in tumour blood flow is not necessarily a contraindication to the use of H33342 for detection of intermittent tumour perfusion and acute hypoxia using histologic or radiobiologic techniques.
Materials and methods
Mice and tumours Experiments were performed using murine SCCVII carcinoma, a rapidly growing, poorly differentiated squamous cell carcinoma, implanted subcutaneously (s.c.) as a single cell suspension in 6-8-week-old male C3H/He mice. Details of the origin and maintenance of this tumour has been published previously . For Trotter et al., 1989b) (Molecular Probes Inc., Eugene, OR, USA) was dissolved in dimethylsulphoxide (DMSO) and diluted to 75% DMSO with PBS prior to intravenous injection. The stain was injected at a dose of 1 mg kg-' in 50 Ild. DiOC7(3) has known vasoactive effects, and therefore in some experiments, fluorescent zinc cadmium sulphide particles (1-10 lim in size; 30 mg ml-', 100 il injection volume; Duke Scientific, Palo Alto, CA, USA) were substituted for DiOC7(3) as the second vascular marker in a double staining protocol .
Tumour and normal tissue bloodflow Blood flow in tumour tissue and in normal skin was measured using laser Doppler flowmetry (Haumschild, 1986; Shepherd et al., 1987) . Details of the experimental method have been published previously (Trotter et al., 1989b,c The effect of H33342 (0-400 ytg ml-') on relative oxygen utilisation of disaggregated SCCVII tumour cells was measured in vitro using the method described by Biaglow and Durand (1976) . The decrease in dissolved oxygen concentration in a stirred cell suspension (5.0 x 10 cells ml-') held at 37°C was measured in a closed reaction vessel with a Clark-type oxygen electrode (Yellow Springs Instrument Co., Yellow Springs, OH, USA).
Measurements of blood P02, CO2, pH, haematocrit, and haemoglobin saturation were made before and after injection of H33342 (15 mg kg-'). Orbital sinus blood samples were collected in microhaematocrit tubes and blood was analysed using an automated blood gas analyser (ABL300) connected via a serial interface to an oximeter (OSM3) for measurement of haemoglobin saturation (Radiometer, Copenhagen, Denmark). The required sample volume was 35 ,ll and all measurements were performed at 37°C.
Double fluorescent labelling technique
An in vivo double-labelling method, designed to identify regions of transient tumour perfusion, has been described in detail previously (Trotter et al., 1989a) . Sequential i.v. injection of two fluorescent vascular markers (H33342 and the carbocyanine dye DiOC7(3)) allows detection, in tumour frozen sections, of vessels with unmatched staining resulting from transient vessel nonperfusion. Blood vessels stained only with H33342 (injected first) are said to have 'closed' during the interval between stain injections. Conversely, vessels outlined only by DiOC7(3) (injected second) have 'opened'. Use of this terminology does not imply that collapse of the vessel lumen is responsible for staining mismatch, only that the vessel was temporarily non-perfused. Double-labelling experiments were performed in s.c. SCCVII tumours and the interval between stain injections was varied from 5 to 60 min. H33342 was injected at a dose of 15 mg kg-' and DiOC7(3) at a dose of 1 mg kg-1. Mice were killed 5 min after DiOC7(3) injection. In some experiments, fluorescent zinc cadmium sulphide particles were injected in place of DiOC7(3).
Radiation response
To determine if H33342 influenced tumour oxygenation and thus the tumour response to radiation, the stain was administered at varying intervals before and after an X-ray dose of 10 Gy. SCCVII tumours in unanaesthetised, restrained mice were locally irradiated, using parallel opposed fields, at a dose rate of 3.16 Gy min-' using a 250 kVp X-ray source. H33342 was given i.v. in 50 flI volume 20 min before, immediately before, or 20 min after irradiation. Some mice were killed 5 min after H33342 injection and the tumours then irradiated to obtain the response of a completely anoxic cell population. Following treatment, tumours were excised and enzymatically dissociated to a single cell suspension as described previously . Cells were then incubated for 1-2 min with fluorescein isothiocyanate (FITC)-labelled anti-mouse IgG (whole molecule; Sigma) to stain non-tumour host cells, predominantly macrophages (Olive, 1989) . Cells were anlaysed using fluorescenceactivated cell sorting (FACS 440, Becton-Dickinson, Sunnyvale, CA, USA): equal numbers of FITC-negative (i.e. tumour) cells were sorted into 10 fractions based on cellular H33342 concentration. The clonogenicity of each fraction was assessed by plating cells, counted by the cell sorter, into 100 mm plastic cell culture plates and incubating in 5% 02, 5% CO2, and 90% N2 at 37°C for 10 days. Colonies were then stained with malachite green and counted.
Results
Tumour bloodflow H33342 caused a dose-dependent reduction in tumour red blood cell (RBC) flow in the SCCVII carcinoma as measured by laser Doppler flowmetry (Figures 1 and 2 ). In immobilised mice (ketamine/diazepam anaesthesia) bearing subcutaneous back tumours, an H33342 dose of 15 mg kg-' reduced RBC flow to 19 ± 11% of normal with a return to pretreatment flow in <7 min (Figure 1) . In foot tumours, the decline in RBC flow was less pronounced in both anaesthetised (50 ± 15% of normal) and unanaesthetised mice (52 ± 14% of normal). In foot tumours, RBC flow was significantly different from pretreatment values for only 2-3 min postinjection. A dose of 5 mg kg' was not significantly vasoactive ( Figure 2) . No long-term reductions in flow were observed using this method. In back tumours, the number of moving RBCs (indicative of functional microvascular volume) also declined following H33342 administration (15 mg kg-') (59% of normal, P<0.001) but this effect was much less pronounced in foot tumours (74% and 89% of normal with and without anaesthesia respectively, P <0.05). Most of the tumour blood flow reduction induced by H33342 was a result of a decrease in mean RBC velocity: in back tumours RBC velocity declined to 31% of pretreatment values while in foot tumours velocity decreased to 62% in anaesthetised mice and to 58% in unanaesthetised mice (P<0.001). Blood flow reduction was observed in tumours ranging in size from 50 to 1,000 mg. Flow reduction in large back tumours> 800 mg was not significantly different than that of small tumours <200 mg (19 ± 12% of pretreatment values vs 21 ± 7%). H33342 had no significant effect on blood flow in skin of a non-tumour-bearing foot. The maximum decline in blood pressure was 20± 6 mmHg (range 11-26mmHg) which is statistically significant (P<0.005). No significant change in heart rate was observed.
Blood pressure/heart rate H33342 caused a transient reduction in mean arterial blood pressure measured directly in anaesthetised C3H/He mice ( Figure 3 ). Blood pressure declined following i.v. H33342 injection in all five animals tested. Pretreatment blood pressure was 86±4 mmHg. The minimum pressure recorded after H33342 injection was 66-± 9 mmHg and thus the maximum decrease in blood pressure was 20 ± 6 mmHg (range 11-26 mmHg; P<0.005). Blood pressure remained significantly lower than pretreatment values up to 23 min after H33342 injection (P<0.05), although a return to near baseline levels occurred by 14 min. Heart rate was not significantly changed.
Metabolic parameters H33342 at concentrations as high as 400 gxg ml-' had no significant effect on oxygen utilisation by SCCVII cells in vitro. A concentration of 400 Lg ml1' would be expected to produce tumour intracellular H33342 concentrations at least 100 x those achievable in vivo . Oxygen consumption (relative to untreated cells) was 0.99 ± 0.07 (n = 6) and 0.92 ± 0.08 (n = 10) for H33342 concentrations of 100 pg ml ' and 400 fig ml-' respectively. Venous blood pH, PO2, and pCO2 were not significantly altered following H33342 administration (Table I) . A slight drop in systemic haematocrit was noted but this was also seen in control animals and was likely the result of repeated orbital sinus blood sampling. No effect on the oxygen-haemoglobin dissociation curve was observed. H33342 had no effect on rectal skin, or tumour temperature (data not shown).
Transient tumour perfusion
In a previous report (Trotter et al., 1989a) , when H33342 and DiOC7(3) injections were separated by a 20 min interval, 8.9 ± 2.4% of vessels in 500 mg s.c. SCCVII tumours exhibited staining mismatch indicative of transient perfusion. Small tumours (4 100 mg) did not show significant levels of staining mismatch. To further validate the use of H33342 as the first vascular marker in a double staining regimen, the interval between stain injections was varied between 5 and 60 min. If H33342-induced transient reductions in tumour perfusion affect the staining mismatch levels obtained then mismatch should decline with increasing injection interval. In addition, vessel closing would presumably predominate relative to vessel opening. No significant difference in mismatch levels was noted for injection intervals of 15 to 60 min (Table II) all intervals, the overall mismatch was significantly greater than when stains were injected simultaneously (P<0.01). The overall staining mismatch observed using a 20 min interval in this series of experiments (performed as a group over a 2-month period) was 5.4+ 1 .8% (n = 15, tumour weight 560 ± 210 mg) a value less than the 8.9 ± 2.4% found in earlier similar experiments (Trotter et al., 1989a) . Similar tumour transplant generations were used and we have no explanation for the slightly reduced level of staining mismatch observed in the present study.
An injection interval of 5 min resulted in a highly variable, artifactually elevated staining mismatch (11.8 ± 11.7%) with a disproportionate amount of vessel closure (H33342, no DiOC7(3)) (Figure 4) due to the vasoactive effect of H33342. Apart from this 5 min injection interval, no significant increase in vessel closing relative to vessel opening was observed.
If fluorescent particles were used in place of DiOC7(3) Jirtle, 1988) then vessels marked with intraluminal particles and not H33342 represented those that opened in the interval between injections. In SCCVII tumours, 6.4% of vessels were found to have opened using this method (data not shown), demonstrating that DiOC7(3) itself is not responsible for reperfusion of previously nonperfused vessels. (DiOC7(3), no H33342) and those which 'closed ' (H33342, no DiOC7(3)) during the interval between stain injections. Levels of statistical significance for non-simultaneous injections vs controls (interval = 0) are as follows: ap < 0.05; bp<0.01; cp<0.001. i r dimly stained cells distant from the blood supply. These results are consistent with observations that H33342 transiently reduced tumour perfusion; reduction in tumour blood flow will cause impaired oxygen delivery, tumour cell hypoxia, and a relative resistance to X-irradiation.
Discussion
The results of this study clearly indicate that the vascular marker H33342 has vasoactive properties in the C3H/He mouse; the stain causes a decrease in tumour blood flow and a transient decline in mean arterial blood pressure. Several important observations require emphasis: (1) reductions in tumour RBC flow are dose-dependent and transient; (2) 5 mg kg-' H33342 is not significantly vasoactive; (3) flow reductions are independent of tumour size; (4) foot tumours show a smaller, <3 min reduction in RBC flow; (5) anaesthesia does not potentiate the maximum H33342-induced flow reduction seen in foot tumours; (6) H33342 has no significant effect on skin RBC flow.
The mechanism responsible for H33342-induced reductions in tumour perfusion is not clear, but, based on observations by Algire and Legallais (1951) , we hypothesised that small changes in mouse blood pressure might explain the apparently selective decrease in tumour flow. Indeed, H33342 causes a transient but significant decline in mouse blood pressure measured by direct arterial cannulation in anaesthetised animals. The time course of blood pressure changes is not, however, identical to that of tumour blood flow reductions, and therefore, perturbations in systemic pressure probably do not entirely explain H33342-induced effects on tumour perfusion. A direct effect of H33342 on tumour blood vessels is possible, but no obvious reason for this selectivity is immediately apparent.
A reduction in blood flow results in decreased tumour oxygenation as evidenced by the increased cell survival seen if tumours are irradiated immediately after H33342 injection. This H33342-induced radioresistance is unlikely to be due to a direct radioprotective effect of the stain (Smith & Anderson, 1984; Young & Hill, 1989) since no tumour cell radioprotection has been observed even after in vivo administration of 400 fig g' (Young & Hill, 1989) , a dose 25 x that used in the radiobiologic experiments described in this study.
H33342 has no significant influence on other physiologic/ metabolic parameters measured. Heart rate, temperature, venous blood gases, pH, haematocrit, and oxyhaemoglobin saturation are unchanged. Exposure of SCCVII tumour cells in vitro to high H33342 concentrations has no effect on relative oxygen utilisation rate of the cells.
We believe that H33342-induced reductions in tumour blood flow are not causally related to the phenomena of transient tumour perfusion and acute hypoxia. Several lines of evidence support this conclusion. (1) Mean tumour cell fluorescence increases linearly as a function of injected H33342 dose (Chaplin & Acker, 1987) indicating that large doses of H33342, while vasoactive, do not cause instantaneous tumour vessel non-perfusion and reduced stain delivery. (2) In double-labelling experiments, approximately equal numbers of opening vessels and closing vessels are observed at intervals between stain injections of > 5 min. If H33342 had prolonged adverse effects on tumour perfusion, vessel closing would be expected to predominate over vessel opening. Vessel opening can also be demonstrated if fluorescent particles are used in place of DiOC7(3) as the second vascular marker. An ideal control experiment for the double staining method would involve injection of DiOC7(3) at some interval before H33342, i.e. the sequence of stain injection would be reversed. However, DiOC7(3), like H33342, causes an abrupt transient decrease in tumour RBC flow, but this is followed, after a brief period of recovery, by a significant prolonged decline in perfusion (Trotter et al., 1989b) . This effect precludes the use of DiOC7(3) as a first marker in a double staining regimen. (3) Small SCCVII tumours do not exhibit staining mismatch indicative of transient vessel nonperfusion (Trotter et al., 1989a ) and yet such tumours show a flow reduction after H33342 identical to that observed in larger tumours. Thus, the degree of H33342-induced reduction in tumour blood flow is not causally linked to transient vessel nonperfusion. (4) H33342 injection 20 min prior to X-irradiation results in the same tumour cell survival as when the stain is injected 20 min after irradiation. Therefore, in support of the results obtained with laser Doppler flowmetry, H33342 reductions in tumour oxygenation are short-lived and no evidence of radiobiologic hypoxia is observed 20 min after stain injection.
These results indicate that H33342 can be used as a marker of functional tumour vasculature in experiments designed to identify transient perfusion (or the resulting acute hypoxia) provided several limitations are kept in mind. First, high doses of H33342 should be avoided. Unfortunately, the nonvasoactive dose (in anaesthetised mice) of 5 mg kg-' does not provide sufficient fluorescence in tumour tissue sections to allow accurate vessel counting using fluorescence microscopy. A slightly higher dose might perhaps be employed when using tumours grown in other sites (e.g. foot) and when anaesthesia is avoided. In our laboratory, cell sorting experiments are routinely performed using in vivo H33342 doses of 10mgkg-' administered to unanaesthetised mice. Second, because H33342 reduces tumour perfusion for several minutes, the second marker in a double staining protocol should be injected at least 7 min after H33342, when (following doses < 15 mg kg-') flow in back tumours has returned to pretreatment levels. This places a limit on the temporal resolution achievable using this technique. Similarly, H33342 should be injected at least 7 min before irradiation, or alternatively, after irradiation. It should be stressed that these conclusions apply only to the SCCVII carcinoma implanted subcutaneously in the back. Shorter intervals can likely be safely employed using foot tumours. Other tumours types or implantation sites may exhibit a different response to H33342 injection. It should be noted that in SCCVII foot tumours, laser Doppler measurements were performed with a surface probe; sampling of some skin microvasculature may explain the less pronounced RBC flow reduction induced by H33342 in this tumours site compared to back tumours (probe placed in direct contact with peripheral tumour tissue). Finally, the effect of intravenous infusion of H33342 was not examined in this study; preliminary results suggest that infusion of 10 mg kg-' H33342 (dose required for cell sorting) over 20-30 min causes no changes in SCCVII RBC flow (unpublished observations).
In summary, H33342 has vasoactive properties; that is, the stain causes a decrease in mean arterial blood pressure and a transient dose-dependent decline in tumour blood flow. These effects impose certain temporal restrictions when the stain is employed in histological and radiobiological techniques. If these limitations are observed, the use of H33342 does not appear to be causally related to the phenomena of transient perfusion and acute hypoxia. 
